CD44v6、C-erbB-2在肺癌中的表达及预后意义(英文)  

Expession and prognostic significance of CD44v6 and C-erbB-2 in lung carcinomas

作　　者：张卿[1] 吴鄂生[1] 陈琼[1] 杨红忠[1] 

机构地区：[1]中南大学湘雅医院呼吸内科,湖南长沙410008

出　　处：《中国现代医学杂志》2004年第3期57-61,共5页China Journal of Modern Medicine

摘　　要：目的　研究CD4 4v6、C -erbB - 2基因在肺癌中的表达及临床意义。方法　采用免疫组化S -P法 ,检测CD4 4v6、C -erbB - 2基因蛋白在 116例肺癌中的表达。结果　在SCLC中 ,CD4 4v6、C -erbB - 2均不表达。在NSCLC中 ,CD4 4v6在鳞癌中的阳性表达率为 6 6 .7% ,腺癌为 36 .1% (P <0 .0 1)。C -erbB - 2在鳞癌中的阳性表达率为 4 7.8% ,腺癌为 6 6 .7% (P >0 .0 5 )。癌旁正常肺组织均未见CD4 4v6、C -erbB - 2的表达。CD4 4v6表达与NSCLC的肿瘤T分期、淋巴结转移、临床分期及生存率有关 (P <0 .0 5 ) ,而与病理分级无关 (P >0 .0 5 )。C -erbB - 2表达与NSCLC淋巴结转移、临床分期及生存率有关 (P <0 .0 5 ) ,而与肿瘤病理分级及肿瘤T分期无关 (P >0 .0 5 )。NSCLC中CD4 4v6与C -erbB - 2表达无相关性 (P >0 .0 5 )。结论　CD4 4v6、C -erbB - 2不仅可作为鉴别SCLC与NSCLC的参考指标 ,而且CD4 4v6、C -erbB - 2阳性表达的患者易发生淋巴结转移、病期较晚、预后差 ,故二者还可作为判断NSCLC预后的较可靠的指标。Objective:To study the expression and the significance of CD44v6 and C-erbB-2 in lung carcinomas.Methods:S-P immunohistochemical method was used to study the expression of CD44v6 and C-erbB-2 in 116 cases of lung carcinomas.Results:There was no positive expression of both CD44v6 and C-erbB-2 in all the 11 SCLC cases.In NSCIC,CD44v6 positive expression was showed in 46 squamous cell carcinomas (66.7%) and in 13 adenocacinomas (36.1%)(P<0.01).C-erbB-2 positive expression was seen in 33 squmous cell carcinomas (47.8%)and 24 adenocaconomas (67.7%) (P>0.05).The positive expression of both CD44v6 and C-erbB-2 showed to be a significant marker for NSCLC.No CD44v6 and C-erbB-2 positive expressions were seen in normal lung tissue near the tumor.CC44V6 positive expression was correlated with tumor T stages,lymphatic metastasis,clinical stages and survival rates in NSCLC(P<0.05)and not correlated with pathologic grades(P>0.05).C-erbB-2 positive expression was associated with lymphatic metastasis,clinical stages and suivival rates(P<0.05).C-erbB-2 positive expression was not associated with pathologic grades and tumor T stages in NSCLC(P>0.05).There was no statistically significant correlation between CD44v6 and C-erbB-2 expression in NSCLC(P>0.05).Conclusions:The results suggested that both CD44v6 and C-erbB-2 are not only considered to distinguish SCLC from NSCLC but also considered as the indicators for evaluating the prognosis of NSCLC because lung carcinomas with positive expression of CD44v6 and C-erbB-2 are likely to develop lymphatic metastasis and result in poor prognosis.

关 键 词：CD44V6 C-ERBB-2 肺癌 免疫组化 

分 类 号：R734[医药卫生—肿瘤]